Treatment with CCL24-neutralizing antibody (CM-101) in preclinical models of SSc and other inflammation and fibrosis-related models has shown robust efficacy in attenuating inflammation and fibrosis. This evidence concerns the gene CCL24 and systemic sclerosis.